The Impact or a Single Dose of Psilocybin on Chronic Suicidal Ideation

[Chip (OP)]

https://www.psychiatrist.com/jcp/efficacy-safety-single-dose-psilocybin-chronic-suicidal-ideation-open-label-trial/?utm_source=Klaviyo&utm_medium=email&utm_campaign=FOM_New_5%2F29%20Approved&klid=01HYSTTNXNB74YAYKT9XMYQCN0&_kx=va3uRF3O8-7Dg_zjrKMZJk0wdery-TOTVyZ3l8muM1g.VpkqxC

Efficacy and Safety of a Single Dose of Psilocybin for Chronic Suicidal Ideation: An Open-Label Trial

May 13, 2026


NB: This is  only the beginning of the abstract, the video and the conclusion.

Objectives:

 To evaluate the efficacy, safety, and durability of a single 25-mg dose of a proprietary, synthetic formulation of psilocybin with psychological support for reducing chronic suicidal ideation in a treatment-resistant population.

Conclusion:

Despite these limitations, this pilot study provides a strong preliminary signal that psilocybin-assisted therapy warrants further investigation as a treatment for chronic suicidal ideation. A single dose of psilocybin was associated with rapid, robust, and durable reductions in suicidal ideation and depression. Future studies should employ a suitable comparator group and include long-term follow-up to assess the full durability of treatment effects.

Vdeo:

i=ePnDKsiBAbepkbZA